This study investigates borderline resectable pancreatic ductal adenocarcinoma. It focuses on collecting samples and information from patients undergoing standard neoadjuvant treatment.
The study evaluates if biomarkers in blood or tumor tissue can help select the best treatment for future patients. It focuses on understanding the link between biomarkers and treatment response.
- Who can participate: Participants must have confirmed pancreatic ductal adenocarcinoma that is either borderline resectable or resectable. They also need to have archival tumor tissue available and a performance status of 1 or less.
- Study details: Participants will undergo standard neoadjuvant treatment and provide blood and tumor samples. A placebo is not involved in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand